This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1359 entries already.
The case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.
Swiss MoonLake Immunotherapeutics AG has secured up to US$500m in non-dilutive financing from life sciences debt specialist Hercules Capital to finance the potential 2027 launch of sonelokimab in hidradenitis suppurativa and clinical trials of the IL-17 dimerisation blocker in palmoplantar pustulosis and other inflammatory indications.
Europe’s decision on how to combine economic growth and decarbonisation in the future depends on the renewal of the EU bioeconomy strategy. The question is whether the EU will fall further behind globally or whether bioeconomy will become the EU’s growth engine.
The Society for Laboratory Automation and Screening (SLAS) has selected 12 start-ups to exhibit at Europe’s premier automation conference as part of its Innovation AveNew programme at SLAS Europe 2025, which takes place from 20-22 May in Hamburg, Germany.
A drug named nitisinone, EU-approved for the treatment of metabolic diseases, also shows strong mosquito-killing properties. According to researchers headed by Lee Haines, it turns human blood toxic to Anopheles mosquitoes that transmit Plasmodium falciparum, the most deadly form of malaria.
Researchers at the Max Planck Institute of Biochemistry (MPIB) and MRC Laboratory of Molecular Biology in Cambridge have developed and patented the new UbiREAD technology, which decodes the complex ubiquitin code that marks target proteins for E3 ligase-mediated degradation in cells.
Leuven-based Augustine Therapeutics NV will use the proceeds from a €77.7m in Series A financing led by Novo Holdings and Jeito Capital to advance its preclinical HDAC6 inhibitor AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease to Phase I testing.
The House of Lords Science and Technology Committee wants to improve technology transfer in industrial biotechnology through better regulation, more funding, and improved access to scale-up infrastructure for biomanufacturing and bioengineering start-ups.
French Sanofi SA announced that it will acquire Dren Bio Inc’s bispecific myeloid cell engager DR-0201 for upfront US$600m and US$1.3bn in milestones. The deal is expected to close in Q2/2025.
University of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke and lung fibrosis.